DGAP-News: Cytos provides update of Phase 2b clinical trial of CYT003 in allergic asthma
(firmenpresse) - EquityStory AG-News: Cytos Biotechnology AG / Key word(s): Research
Update
Cytos provides update of Phase 2b clinical trial of CYT003 in allergic
asthma
16.01.2013 / 07:00
---------------------------------------------------------------------
Cytos provides update of Phase 2b clinical trial of CYT003 in allergic
asthma
Guidance for top-line results in 1H 2014 reiterated
Schlieren (Zurich), Switzerland, January 16, 2013 - Cytos Biotechnology Ltd
(SIX:CYTN) today announced an update on the Phase 2b clinical trial with
its lead product candidate, CYT003, in allergic asthma. The clinical trial
will recruit approximately 360 adult patients with moderate to severe
allergic asthma not sufficiently controlled on current standard therapy.
The study will be conducted at more than 90 centers in North America and
Europe, and is expected to read out top-line data in 1H 2014. Regulatory
approvals to conduct the trial have been obtained in various countries in
Europe and North America including the United States, where an IND
(Investigational New Drug) application has been approved by the US Food&Drug Administration.
In the course of periodic drug quality measurements, a technical issue was
identified with the rubber stoppers used to close the injection vials
containing the clinical trial material. Cytos will replace this clinical
trial material and have new material available at clinical trial sites in
Q2 2013.
Overall guidance for the clinical trial remains unchanged. Cytos expects to
have top-line data available in the course of 1H 2014 and full data towards
the end of 2014.
Christian Itin, Chairman and CEO of Cytos Biotechnology, comments: 'We
appreciate the support of our investigators and are looking forward to
evaluating CYT003 in patients with allergic asthma.'
###
For further information, please contact:
Cytos Biotechnology Ltd
Harry Welten
Chief Financial Officer
Tel: +41 44 733 46 46
e-mail: harry.welten(at)cytos.com
US Investor enquiries
Susan A. Noonan
Tel: +1 (212) 966 3650
e-mail: susan(at)sanoonan.com
About Cytos Biotechnology Ltd
Cytos is a public biopharmaceutical company focused on the development of
targeted immuno-therapies. The Company's lead product candidate CYT003 is a
first-in-class biologic in Phase 2 clinical development as a potential new
treatment for allergic asthma.
CYT003 acts via a novel, allergen-independent mechanism of action to
selectively suppress the body's immune response to allergens, a predominant
risk factor for asthma. In a successfully completed Phase 2a study, CYT003
was shown to maintain asthma control and lung function and asthma control
in patients with persistent allergic asthma, even as standard inhaled
corticosteroid treatment was withdrawn. CYT003 has been shown to be safe in
over 450 patients to date.
Cytos was founded in 1995 as a spinoff from the Swiss Federal Institute of
Technology (ETH) in Zurich. It is located in Schlieren (Zurich),
Switzerland. The Company is listed according to the Main Standard on the
SIX Swiss Exchange Ltd under the symbol CYTN.
www.cytos.com
This foregoing press release may contain forward-looking statements that
include words or phrases such as 'are intended for', 'are designed to', or
other similar expressions. These forward-looking statements are subject to
a variety of significant uncertainties, including scientific, business,
economic and financial factors, and therefore actual results may differ
significantly from those presented. There can be no assurance that any
further therapeutic entities will enter clinical trials, that clinical
trial results will be predictive for future results, that therapeutic
entities will be the subject of filings for regulatory approval, that any
drug candidates will receive marketing approval from the U.S. Food and Drug
Administration or equivalent regulatory authorities, or that drugs will be
marketed successfully. Against the background of these uncertainties
readers should not rely on forward-looking statements. The Company assumes
no responsibility to update forward-looking statements or adapt them to
future events or developments.
End of Corporate News
---------------------------------------------------------------------
16.01.2013 This press release was distributed by EQS CORPORATE
COMMUNICATIONS.
www.eqs.com - news archive: www.eqs.com/ch/presskit
The issuer is responsible for the contents of the release.
---------------------------------------------------------------------
Language: English
Company: Cytos Biotechnology AG
Wagistr. 25
8952 Schlieren
Switzerland
Phone: +41 44 733 4747
Fax: +41 44 733 4740
E-mail: info(at)cytos.com
Internet: www.cytos.com
ISIN: CH0011025217, CH0029060735
Swiss Security Number: -
Listed: Freiverkehr in Berlin, München, Stuttgart;
Open Market in Frankfurt; SIX
End of News EquityStory AG News-Service
---------------------------------------------------------------------
199166 16.01.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 16.01.2013 - 07:00 Uhr
Sprache: Deutsch
News-ID 219924
Anzahl Zeichen: 5567
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 277 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Cytos provides update of Phase 2b clinical trial of CYT003 in allergic asthma"
steht unter der journalistisch-redaktionellen Verantwortung von
Cytos Biotechnology AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
